Form 4: MapLight Therapeutics Insider Stock Sale

Chief Discovery Officer Anatol Kreitzer sold 3,316 shares of MapLight Therapeutics to cover tax obligations.

Summary

• Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics, Inc. (MPLT), sold 3,316 shares of Voting Common Stock.
• The transaction occurred on April 15, 2026.
• The shares were sold at a weighted average price of $26.61 per share.
• Following the transaction, the reporting person retains beneficial ownership of 256,612 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and mandated by tax requirements rather than a reflection of management sentiment.

Positives

• The sale was executed to satisfy statutory tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary market exit.

Negatives

• Reduction in direct equity stake held by a key executive.

Risks

• None identified; this is a routine administrative transaction related to tax compliance.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this is a standard 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently vest in equity-based compensation and must sell a portion of those shares to satisfy immediate tax liabilities.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance in the U.S. biotech industry.

Stakeholder Impact

• Minimal impact on shareholders as the sale was for tax compliance purposes.

Next Steps

• None

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, SEC Filing, Anatol Kreitzer